Polyrizon Unveils Preclinical Intranasal Hydrogel Blocking Respiratory Viruses
PLRZ•Polyrizon’s preclinical Capture&Contain™ intranasal hydrogel has shown in vitro blockade of multiple respiratory viruses, including influenza and coronaviruses, preserving cell viability in dynamic exposure models. The non-specific barrier technology addresses emerging Hantavirus clusters and aims for immediate deployability prior to strain-specific vaccines.
1. Technology Overview
Polyrizon’s Capture&Contain™ platform employs proprietary polysaccharide formulations that rapidly form a thin biophysical layer on the nasal mucosa, creating a mechanical barrier designed to interfere with viral entry at the primary infection site.
2. Laboratory Efficacy
In controlled in vitro and dynamic exposure models, treated cell cultures demonstrated significant reduction in viral-host interactions across influenza and coronavirus families, with consistent preservation of cell viability compared to untreated controls.
3. Market Implications
Recent clusters of Hantavirus and other respiratory threats underscore the need for non-specific defense tools that can be deployed immediately, offering governments and health systems a complementary measure before strain-specific vaccines and therapeutics are available.
4. Development Outlook
PL-16, the lead Viral Blocker candidate based on the Capture&Contain™ technology, remains in preclinical stages; further clinical evaluation will determine its potential as a strategic asset in pandemic preparedness and respiratory protection.
